Notably, we show that STAT3 activation is elevated in Olaparib-resistant ovarian cancer cells, and genetic or pharmacological STAT3 inhibition can effectively reduce PARPi-resistant cell proliferation. The gene discussed is STAT3; the disease is ovarian carcinoma.